Reactome | NR3C2 binds fludrocortisone

NR3C2 binds fludrocortisone

Stable Identifier

R-HSA-9726509

Type

Reaction [binding]

Species

Homo sapiens

Compartment

cytosol, extracellular region

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Fludrocortisone is a synthetic mineralocorticoid used in conjunction with hydrocortisone to replace missing endogenous corticosteroids in patients with adrenal insufficiency. It is functionally similar to aldosterone, the body's primary endogenous mineralocorticoid, and is structurally analogous to cortisol, differing only by a fluorine atom at the 9-position of the steroid structure and having similar affinity for the mineralocorticoid receptor (NR3C2) as aldosterone (Rupprecht et al. 1993, Oelkers et al. 1994).

Fludrocortisone is indicated as partial replacement therapy for primary or secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing androgenital syndrome (Charmandari et al. 2014, Hamitouche et al. 2017). Fludrocortisone has also shown to be effective in the treatment of cerebral salt-wasting syndrome (Taplin et al. 2006, Misra et al. 2018). Common side effects of fludrocortisone include high blood pressure, swelling, heart failure, and low blood potassium.

Literature References

PubMed ID	Title	Journal	Year
8282004	Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands Rupprecht, R, Reul, JM, van Steensel, B, Spengler, D, Söder, M, Berning, B, Holsboer, F, Damm, K	Eur. J. Pharmacol.	1993
8157723	Impaired renal 11 beta-oxidation of 9 alpha-fluorocortisol: an explanation for its mineralocorticoid potency Oelkers, W, Buchen, S, Diederich, S, Krain, J, Muhme, S, Schöneshöfer, M	J Clin Endocrinol Metab	1994
28083797	Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers Hamitouche, N, Comets, E, Ribot, M, Alvarez, JC, Bellissant, E, Laviolle, B	AAPS J	2017